OCUL News and Press, Ocular Therapeutix Inc. From 06/07/24

2024-06-07 11:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consu...

BEDFORD, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-relate...

2024-06-03 14:01:10 ET Summary Ocular Therapeutix is a biopharmaceutical company with a successful commercial product, Dextenza, generating $57.9 million in revenue in 2023. The company's main value driver is Axpaxli, an axitinib intravitreal implant in phase 3 trials for wet age-...

2024-06-01 05:30:37 ET Summary Ocular Therapeutix has provided promising updates on its clinical trials for Axpaxli and Paxtrava, utilizing its Elutyx drug-eluting platform. The company has appointed a new CEO and raised funds, extending its cash runway until 2028. Ocular's pi...

2024-05-28 17:04:47 ET Gainers: Blue World Acquisition  ( BWAQ ) +57% . Insmed  ( INSM ) +33% . Vivid Seats  ( SEAT ) +8% . Ocular Therapeutix ( OCUL ) +7% . Mind Medicine  ( MNMD ) +7% . Losers: Inhib...

2024-05-07 16:35:53 ET More on Ocular Therapeutix Ocular Therapeutix's Impressive Surge: A Strategic Insight Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement Ocular Therapeutix Q1 2024 Earnings Preview Baird sees weakness in Ocula...

Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Ba...

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related...

2024-05-06 08:26:44 ET More on pre-market losers & stocks. GameStop: Approaching An Optimistic Fair Value But Not There Yet GameStop: Operations Are Stabilizing, But Expect More Pain To Come Predictive Oncology Inc. (POAI) Q4 2023 Earnings Call Transcript ...